Guangdong Xinminghong Biotechnology Co., Ltd. – Trademark Portfolio
Entity Type: 99
Guangdong Xinminghong Biotechnology Co., Ltd. holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 1 trademark is registered and 1 is pending. Notable registered marks include DIDORIO. The owner is based in Shenzhen City, Guangdong Province.
Room 303, Building 2, No. 7 Xikeng South Road, Xikeng Community, Fucheng Subdistrict, Longhua District,
Shenzhen City, Guangdong Province 518000 , CN
Showing of trademarks Trademarks
Trademark Classifications
Guangdong Xinminghong Biotechnology Co., Ltd.'s trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Guangdong Xinminghong Biotechnology Co., Ltd. have?
Guangdong Xinminghong Biotechnology Co., Ltd. has 2 U.S. trademarks filed with the USPTO. Of these, 1 registered, 1 pending.
What trademark classes does Guangdong Xinminghong Biotechnology Co., Ltd. file in?
Guangdong Xinminghong Biotechnology Co., Ltd. files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Guangdong Xinminghong Biotechnology Co., Ltd.'s most well-known trademarks?
Guangdong Xinminghong Biotechnology Co., Ltd.'s registered trademark portfolio includes well-known marks such as DIDORIO. These are among 1 currently registered trademark in the portfolio.
What is Guangdong Xinminghong Biotechnology Co., Ltd.'s trademark registration success rate?
Guangdong Xinminghong Biotechnology Co., Ltd. has a 100% trademark registration rate, with 1 out of 1 resolved applications resulting in successful registration. Currently, 1 application is pending review.